| News Updates |
 |
FDA approves label update to ViiV's long-acting HIV treatment
Outsourcing Pharma | April 26, 2022
|
|
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
The Lancet | April 20, 2022
|
|
Risk for Incident Liver Damage in Patients With HIV on Antiretroviral Therapy
Infectious Disease Advisor | April 12, 2022
|
|
Counterfeit HIV Drugs: Justice Department Opens Investigation
Medscape | April 11, 2022
|
|
Provider Survey: Prior Authorizations Harm Patients
CANN | April 4, 2022
|
|
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
The Lancet | April 1, 2022
|
|
FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for Children Living With HIV
Contagion Live | March 30, 2022
|
|
ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
MarketScreener | March 30, 2022
|
|
Uncertain Future for 2 Long-Acting HIV Therapies
Infectious Disease Special Edition | March 30, 2022
|
|
FDA makes oral lead-in optional for long-acting injectable HIV regimen
Healio | March 24, 2022
|
|
Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician
Fierce Pharma | March 8, 2022
|
|
FDA rejects Gilead's HIV drug lenacapavir over glass vial concerns
Healio | March 2, 2022
|
|
Evaluation of Sociodemographic Factors and Prevalence of Oral Lesions in People Living with HIV from Cacoal, Rondônia, Amazon Region of Brazil
Int J Environ Res Public Health. 2022 Feb 24;19(5):2614. doi: 10.3390/ijerph19052614.
|
|
Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study
Precision Vaccinations | February 19, 2022
|
|
Cabenuva Approved for 2 Month Injections; Insurers Remain a Barrier to Access
Co-infection Watch | February 2022
|
|
HIV: Dual Therapy With Twice-Yearly Injections on the Horizon
Medscape | February 18, 2022
|
|
Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254)
Infectious Disease Advisor | January 27, 2022
|
|
Clinical Care Options
|
|
Antimicrobial resistance causes more deaths than HIV and malaria
News Medical | January 22, 2022
|
|
HIV Provider Organization to Launch New Web Resource on Long-Acting Agents
American Academy of HIV Medicine | January 6, 2022
|
|
Dolutegravir-Based Treatment More Effective in Children Living With HIV
Contagion Live | January 6, 2022
|
|
Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy
Infectious Disease Advisor | January 5, 2022
|
|
HIV Drug Resistance Report - November 2021
ReliefWeb | November 24, 2021
|
|
Injectable HIV treatment for patients in UK | HIV AIDS | Health News
YouTube | November 22, 2021
|
|
Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter
Aidsmap | November 5, 2021
|
|
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
NIH | November 4, 2021
|
|
NATAP | October 26, 2021
|
|
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results
AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.
|
|
ViiV | 28 September 2021
|
|
Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346
|
|
FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans
docwirenews | September 23, 2021 |
|
Agents Used in Antiretroviral Therapy
Clinical Care Options | September 2021
|
|
Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain
FIU News | September 17, 2021
|
|
First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV
Contagionlive.com | September 10, 2021
|
|
Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.
|
|
Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus
Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728
|
|
Changes to the Epclusa product label for use in pediatrics
FDA | June 2021
|
|
Changes to the Mavyret product labeling for use in pediatrics
FDA | June 2021
|
|
How modern medication has extended the life span of people with HIV over the past 40 years
California News Times | May 2021
|
|
Six drugmakers are in violation of 340B statute, says HRSA
Healthcare Finance News | May 18, 2021
|
|
Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria
Pharmacy Times | May 10, 2021
|
|
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Business Wire | May 4, 2021
|
| |
|
